ArticleAIDS and behavior2025
Pre-Exposure Prophylaxis Care Engagement Among Men Who Have Sex with Men in the United States During the COVID-19 Pandemic: A Scoping Review.
Article in AIDS and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The COVID-19 pandemic substantially impacted the pre-exposure prophylaxis (PrEP) care continuum among men who have sex with men (MSM). While PrEP use during the pandemic has been studied, regional differences in PrEP regulations highlight the need for U.S.-specific reviews. This scoping review evaluates empirical literature on COVID-19's impact on PrEP engagement among U.S. MSM. A systematic search on August 29, 2024, identified articles from PubMed, PsycINFO, and Embase. Eligible studies (a) collected empirical data from U.S. MSM, (b) assessed COVID-19's impact on PrEP engagement, and (c) were peer-reviewed, English-language, full-text articles. Standardized forms were used to extract study information. Study quality was appraised using validated tools for qualitative and quantitative research. Findings were synthesized using descriptive statistics and narrative summaries, categorized by distinct pandemic phases. Of 438 records, 21 studies were included (15 quantitative, five qualitative, one mixed-method), mostly conducted during the lockdown phase. Results showed reduced PrEP use (5.9-35.6%), increased missed doses (8.3-14.2%), and higher discontinuation rates (9.0-33.3%) during COVID-19. Barriers included refill issues (9.0-20.0%), limited access to care (2.5-17.0%), disrupted lab testing (~ 25.5%), and changes in clinic procedures. College-aged youth reported confidentiality concerns after returning home. Qualitative evidence highlighted telehealth and injectable PrEP as promising alternatives. This review reveals significant disruptions to PrEP care for U.S. MSM during COVID-19, a lack of post-lockdown research, underrepresentation of MSM from Northeastern and Pacific regions, and limited use of objective PrEP adherence measures. These findings underscore the need for emergency-prepared PrEP services and expanded telehealth and home-delivery options for future crises.
Indexed as
Identifiers
40465040What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.